

Taguspark, Parque de Ciência e Tecnologia, Edifício Inovação II, 421, 2740-122 Oeiras +351 263 974 652 | contact@heartgenetics.com | www.heartgenetics.com

MOLECULAR TEST REQUISITION FORM

MOLECULAR PATHOLOGIC MARKERS OF HIGH RISK AND PREVALENCE FOR FAMILIAL HYPERCHOLESTEROLEMIA

INDEX PATIENT/ FAMILIAR INFORMATION (obligatory field, delete as applicable)

Gender:
SPECIMEN SOURCE (Obligatory field) Whole blood
Whole blood DNA Saliva PHYSICIAN INFORMATION (obligatory field) Physician Address Institution: Department: E-mail: Department: Departm
PHYSICIAN INFORMATION (obligatory field) Physician
Physician
Address Institution:
Institution:
MOLECULAR TEST REQUESTED (obligatory field) Molecular pathologic markers of high risk and prevalence for familial hypercholesterolemia Evaluation of genetic mutations of LDLR gene that cause familial hypercholesterolemia and that are related with 1) high levels of total cholesterol and LDL cholesterol, 2) severe phenotype, 3) increased risk of premature cardiovascular disease and 4) higher frequency in the population. In addition, are evaluated the genetic alterations of ApoE gene that are associated with increased risk of premature cardiovascular disease. PREVIOUS GENETIC CONSULTANCY: Date/
Molecular pathologic markers of high risk and prevalence for familial hypercholesterolemia Evaluation of genetic mutations of LDLR gene that cause familial hypercholesterolemia and that are related with 1) high levels of total cholesterol and LDL cholesterol, 2) severe phenotype, 3) increased risk of premature cardiovascular disease and 4) higher frequency in the population. In addition, are evaluated the genetic alterations of ApoE gene that are associated with increased risk of premature cardiovascular disease. PREVIOUS GENETIC CONSULTANCY: Date/
Molecular pathologic markers of high risk and prevalence for familial hypercholesterolemia Evaluation of genetic mutations of LDLR gene that cause familial hypercholesterolemia and that are related with 1) high levels of total cholesterol and LDL cholesterol, 2) severe phenotype, 3) increased risk of premature cardiovascular disease and 4) higher frequency in the population. In addition, are evaluated the genetic alterations of ApoE gene that are associated with increased risk of premature cardiovascular disease. PREVIOUS GENETIC CONSULTANCY: Date/
Molecular pathologic markers of high risk and prevalence for familial hypercholesterolemia Evaluation of genetic mutations of LDLR gene that cause familial hypercholesterolemia and that are related with 1) high levels of total cholesterol and LDL cholesterol, 2) severe phenotype, 3) increased risk of premature cardiovascular disease and 4) higher frequency in the population. In addition, are evaluated the genetic alterations of ApoE gene that are associated with increased risk of premature cardiovascular disease. PREVIOUS GENETIC CONSULTANCY: Date/
FAMILTAR INFORMATION
Previously studied familial members: identification in genealogical tree. Point out the individual in the present study with an arrow (>).
101 102 103 104 105 106 107 108 109 110 111 112
وجام وجام وجام وجام وجام وجام وجام وجام
201 202 203 204 205 206 207 208 209 210 211 212
201 202 203 204 205 206 207 208 209 210 211 2 ₁₂ 301 302 303 304 305 306 307 308 309 310 311 312

V.1.2 / 2014 Page **1** / **3**



Taguspark, Parque de Ciência e Tecnologia, Edifício Inovação II, 421, 2740-122 Oeiras +351 263 974 652 | contact@heartgenetics.com | www.heartgenetics.com

MOLECULAR TEST REQUISITION FORM

MOLECULAR PATHOLOGIC MARKERS OF HIGH RISK AND

	PREVALENCE FOR FAMILIAL HYPERCHOLESTEROLEMIA Name:
l	Consultancy Referral Number:

Position in the tree	Name / Consultancy Referral Number	Clinical information and age of diagnostic

CLINICAL INFORMATION: COMPLEMENTARY DIAGNOSTIC EXAMS

By filling these fields you are contributing to improve your future patient diagnostics as we are developing tools to model clinical and genetic data regarding. Arterial Hypertension risk factors.

Clinical Informa	ation	cion Data						
Date and age of diag	gnostic	(day) /	(month) /	(^{year}),	years			
Total cholesterol		^{pv tp} mg/dl,	^{af tp} mg/c	ii; LDL-C	^{pv tp} mg/dl ,	af tp mg/dl; HDL		
^{pv tp} mg/	'dl,	^{af tp} mg/dl; VLDL	•	^{pv tp} mg/dl ,	^{af tp} mg/dl, r	non-HLDL cholesterol		
^{pv tp} mg/o	dl,	^{af tp} mg/dl; ApoA	1	mg/dl, ApoB	mg/dl			
(pv tp - previous therap	eutics, af tp	- after therapeutics)						
Personal history of cardiovascular diseases	^(Y) , Coronary Bypass Stroke ^(y)							
Signs								
Associated diseases Tendon xanthomas □, Xanthelasmas □, Arcus senilis □, Fat liver □ Thyroid disease □, Liver disease □, Pancreatic disease □, Autoimmune disease □, Chronic kidney disease □, Arterial hypertension □								
Family history	Family history High cholesterol □, High LDL □, Premature cardiovascular disease (before 55 in a man and before 60 in a woman) □, sudden death □ Associated risk factors Fast food □, Lack of physical activity □, Obesity □, Overweight □, Units of alcohol (1 unit = 1 glass) / week □, Smoking □, no cigarettes /day, no packs /day, stop smoking at years							
Therapeutics								

V.1.2 / 2014 Page **2** / **3**



Taguspark, Parque de Ciência e Tecnologia, Edifício Inovação II, 421, 2740-122 Oeiras +351 263 974 652 | contact@heartgenetics.com | www.heartgenetics.com

MOLECULAR TEST REQUISITION FORM

MOLECULAR PATHOLOGIC MARKERS OF HIGH RISK AND

PREVALENCE FOR FAMILIAL HYPERCHOLESTEROLEMIA Consultancy Referral Number: **ANNEX** Sample tubes labeled with index case / patient / familiar information \square Whole blood (preferable) (Date obtained: ____ / ___), Conditions: 4mL or 2 X 3mL in K_2 EDTA or K_3 EDTA collection tube DNA (Date obtained: ___ / ____); Volume ____μL; Concentration _____ μg/mL; Purification Method: __ Conditions: minimum 300ng of 35ng/µL, Saliva (recommended kit: Oragene DNA collection kit Genotek) **INFORMED CONSENT INFORMATION (IT IS MANDATORY TO BE SIGNED)** for the genetic test specified in this request. I declare that I have been informed about genetic testing features and that I understand the benefits and limitations of the cardiovascular genetic test regarding genetic analysis of hypertrophic cardiomyopathy for which I am giving permission. I give permission for the anonymously processing of the obtained digital data: yes \square no \square I give permission for the biological specimen and clinical information to be anonymously used in research studies: yes $\ \square$ no ; / / 20 Signature Place and Date

Physician signature _____

V.1.2 / 2014 Page 3 / 3